問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
CHANGHUA CHRISTIAN HOSPITAL
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2025-04-01 - 2027-12-31
Condition/Disease
OS (defined as the time elapsed from random assignment to death for any reason)
Test Drug
LIBTAYO THIO
Participate Sites10Sites
Recruiting10Sites
2025-04-01 - 2030-06-18
Advanced hepatocellular carcinoma
Atezolizumab Bevacizumab Rilvegostomig (AZD2936) Tremelimumab
Participate Sites8Sites
Recruiting8Sites
2025-05-01 - 2030-04-30
ORR is defined as the percentage of participants who achieve a complete response (CR) or a partial response (PR) as assessed by BICR according to RECIST v1.1. OS is defined as the length of time elapsed from random assignment until the date of death from any cause.
TRODELVY for Injection
Participate Sites9Sites
Recruiting9Sites
2020-12-01 - 2025-12-31
Participate Sites5Sites
Recruiting5Sites
2022-06-01 - 2032-12-31
2021-05-01 - 2026-12-31
Participate Sites3Sites
Recruiting3Sites
2019-11-01 - 2028-12-31
2021-02-01 - 2027-12-31
Participate Sites6Sites
Recruiting6Sites
2020-09-01 - 2024-09-18
2021-11-01 - 2031-12-31
全部
